Ignite Creation Date:
2024-05-05 @ 10:37 PM
Last Modification Date:
2024-10-26 @ 10:21 AM
Study NCT ID:
NCT01141686
Status:
COMPLETED
Last Update Posted:
2010-06-10
First Post:
2010-06-08
Brief Title:
Non Small Cell Lung Cancer Evaluation According to Pre-determined Drug-targeting Tumor Markers
Sponsor:
Taipei Medical University WanFang Hospital
Organization:
Taipei Medical University WanFang Hospital
Study Overview
Official Title:
Non Small Cell Lung Cancer Evaluation According to Pre-determined Drug-targeting Tumor Markers
Status:
COMPLETED
Status Verified Date:
2010-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Evaluate chemotherapy related tumor markers on non small cell lung cancer by fluorescent in situ hybridization and immunohistochemistry targets to be studied include EGFR c-MET topoisomerase II p53 topoisomerase I thymidylate synthase ERCC1 tau c-myc RRM1 class III tubulin These targets have been chosen because they are targets for chemotherapeutic agents that are currently used in clinical management of these diseases In total 50 specimen will be studied approximately one third have mutationsdeletions of the EGFR geneTo attempt to establish a correlation between the pre-selected tumor markers and response to chemotherapy and thus to be able to create a clinically useful classification that would provide clinical guidance for selection of the most effective chemotherapy for a individual patient and thus be able to logically design more effective clinical trials for the future
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None